Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Systematic Review of the Clinical Impact of GLP-1 Receptor Agonists in Hidradenitis Suppurativa.

American journal of clinical dermatology·2026

Same author

The WHO-5 well-being measure as an assessment tool in eczema, hidradenitis suppurativa and psoriasis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025

Same author

Hidradenitis suppurativa and mortality in Ireland over a 10-year period: an assessment of statistics and review of the literature.

Clinical and experimental dermatology·2025

Same author

Infectious disease.

Clinical and experimental dermatology·2025

Same author

'Growing up with a red nose': a patient's perspective on rosacea.

Clinical and experimental dermatology·2023

Same author

Incidence of cutaneous T-cell lymphoma in the Republic of Ireland between 1994 and 2019.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023

Search research articles

Related Experiment Video

Updated: Oct 14, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Risankizumab-induced paradoxical pustular psoriasis.

O McFeely¹, E Pender¹, L Victory¹

¹Department of Dermatology, Mater Misericordiae University Hospital, Dublin, Ireland.

Clinical and Experimental Dermatology

|November 8, 2021

Summary

This summary is machine-generated.

This case study reports a rare instance of paradoxical pustular psoriasis in a patient treated with risankizumab. This adverse event occurred despite no prior history of pustular psoriasis, highlighting a potential new side effect of the drug.

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

Granulocyte-dependent Autoantibody-induced Skin Blistering

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

Related Experiment Videos

Last Updated: Oct 14, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

Granulocyte-dependent Autoantibody-induced Skin Blistering

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

Area of Science:

Dermatology
Immunology
Pharmacology

Background:

Psoriasis is a chronic autoimmune condition affecting skin.
Risankizumab is an interleukin-31 (IL-31) inhibitor used for treating moderate to severe psoriasis.
Paradoxical reactions, including pustular psoriasis, can occur with biologic therapies.

Observation:

A 45-year-old woman with a 22-year history of psoriasis presented with a sudden onset of pustular psoriasis.
The patient was undergoing treatment with risankizumab for her psoriasis.
The pustular psoriasis affected 60% of her body surface area.

Findings:

This is the first reported case of paradoxical pustular psoriasis associated with risankizumab treatment.
The patient had no prior history of pustular psoriasis, suggesting a drug-induced phenomenon.
The development of pustular psoriasis occurred despite established psoriasis treatment.

Implications:

Clinicians should be aware of the potential for risankizumab to induce paradoxical pustular psoriasis.
Further research is needed to understand the mechanism behind this reaction.
This finding may necessitate monitoring for specific adverse events in patients treated with risankizumab.